Dynavax Technologies Corp (LTS:0IDA)

$ 12.9401 0 (0%) Market Cap: 1.71 Bil Enterprise Value: 1.20 Bil PE Ratio: 100.00 PB Ratio: 2.51 GF Score: 67/100

Q3 2024 Dynavax Technologies Corp Earnings Call Transcript
Nov 07, 2024

$12.29 (+1.03%)

Earnings
Q2 2024 Dynavax Technologies Corp Earnings Call Transcript
Aug 06, 2024

$10.16 (+1.55%)

Earnings
Q1 2024 Dynavax Technologies Corp Earnings Call Transcript
May 08, 2024

$11.71 (-0.83%)

Earnings
Q4 2023 Dynavax Technologies Corp Earnings Call Transcript
Feb 22, 2024

$12.4 (+0.56%)

Earnings
Dynavax Technologies Corp at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Dynavax Technologies Corp Earnings Call Transcript
Nov 02, 2023

$14.22 (+0.51%)

Earnings
Dynavax Technologies Corp at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript
Oct 25, 2023
Q2 2023 Dynavax Technologies Corp Earnings Call Transcript
Aug 03, 2023

$13.59 (+0.74%)

Earnings
Dynavax Technologies Corp at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Dynavax Technologies Corp at William Blair Growth Stock Conference Transcript
Jun 06, 2023
Dynavax Technologies Corp at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Q1 2023 Dynavax Technologies Corp Earnings Call Transcript
May 02, 2023

$10.42 (+1.40%)

Earnings
Q4 2022 Dynavax Technologies Corp Earnings Call Transcript
Feb 23, 2023

$10.8 (-1.98%)

Earnings
Q3 2022 Dynavax Technologies Corp Earnings Call Transcript
Nov 03, 2022

$11.12 (-2.03%)

Earnings
Q2 2022 Dynavax Technologies Corp Earnings Call Transcript
Aug 04, 2022

$14.54 (+2.78%)

Earnings
Q1 2022 Dynavax Technologies Corp Earnings Call Transcript
May 05, 2022

$8.98 (-7.42%)

Earnings
Q4 2021 Dynavax Technologies Corp Earnings Call Transcript
Feb 28, 2022

$12.6 (+1.83%)

Earnings
Q3 2021 Dynavax Technologies Corp Earnings Call Transcript
Nov 04, 2021

$20.69 (-0.24%)

Earnings
Dynavax Technologies Corp at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
Oct 05, 2021
Dynavax Technologies Corp at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Q2 2021 Dynavax Technologies Corp Earnings Call Transcript
Aug 04, 2021

$9.34

Earnings
Dynavax Technologies Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Dynavax Technologies Corp Annual Shareholders Meeting Transcript
May 28, 2021
Q1 2021 Dynavax Technologies Corp Earnings Call Transcript
May 06, 2021

$8.79 (-5.35%)

Earnings
Dynavax Technologies Corp at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021
Q4 2020 Dynavax Technologies Corp Earnings Call Transcript
Feb 25, 2021

$9.25 (+0.24%)

Earnings
Q3 2020 Dynavax Technologies Corp Earnings Call Transcript
Nov 05, 2020

$4.2

Earnings
Q2 2020 Dynavax Technologies Corp Earnings Call Transcript
Aug 06, 2020

$9.11

Earnings
Dynavax Technologies Corp Annual Shareholders Meeting Transcript
May 28, 2020
Q1 2020 Dynavax Technologies Corp Earnings Call Transcript
May 07, 2020

$4.05

Earnings
Dynavax Technologies Corp - To Discuss the Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B - Conference Call Transcript
Apr 30, 2020
Q4 2019 Dynavax Technologies Corp Earnings Call Transcript
Mar 11, 2020

$4.64

Earnings
Q3 2019 Dynavax Technologies Corp Earnings Call Transcript
Nov 06, 2019

$2.83

Earnings
Q2 2019 Dynavax Technologies Corp Earnings Call Transcript
Aug 07, 2019

$2.83

Earnings
Q1 2019 Dynavax Technologies Corp Earnings Call Transcript
May 08, 2019

$6.49

Earnings
Q4 2018 Dynavax Technologies Corp Earnings Call Transcript
Feb 26, 2019

$12.01

Earnings

Q1 2022 Dynavax Technologies Corp Earnings Call Transcript

May 05, 2022 / 08:30PM GMT

Release Date Price: $8.98 (-7.42%)

Transcript 10-Q8-K

Operator

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies First Quarter 2022 Financial Results. As a reminder, this conference call is being recorded. (Operator Instructions)

I would now like to turn the call over to Nicole Arndt, Senior Manager, Investor Relations. You may begin.

Nicole Arndt

Dynavax Technologies Corporation - Senior Manager of IR

Thank you. Good afternoon, and welcome to the Dynavax First Quarter 2022 Financial Results and Corporate Update Conference Call. In addition to our press release issued today, a supplementary slide presentation that accompanies today's call is available in the Events section of our website.

Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to potential market size and market share, impact of ACIP recommendation, financial guidance and trends, expected regulatory filings or approvals of our collaborators, clinical readouts and potential future uses of CpG 1018 adjuvant. These

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.